Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14777629 | 0.78 | — | — | |
| SCHEMBL17375881 | 0.78 | LAP3 (0.33) | LAP3 | |
| SCHEMBL10935251 | 0.76 | LAP3 (0.32) | LAP3 | |
| SCHEMBL18596920 | 0.76 | FDPS (0.35) | LAP3 | |
| SCHEMBL15128196 | 0.74 | FDPS (0.34) | LAP3 | |
| SCHEMBL11688376 | 0.74 | LAP3 (0.35) | LAP3 | |
| SCHEMBL12643184 | 0.74 | FDPS (0.34) | LAP3 | |
| SCHEMBL21101675 | 0.74 | LAP3 (0.31) | LAP3 | |
| SCHEMBL5162415 | 0.74 | PTPN1 (0.42) | — | |
| SCHEMBL8812398 | 0.73 | PTPN5 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741389-A1 | KAT6 INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2024-02-22 | — | — | US | disclosed |
| EP-2917185-B1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | EVOTEC INT GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2917185-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2015-09-16 | — | — | EP | disclosed |
| US-8901138-B2 | Sulfoximine substituted quinazolines for pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-02 | — | — | US | disclosed |
| WO-2014072244-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-15 | — | — | WO | disclosed |
| US-20140135309-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-15 | — | — | US | disclosed |
| US-20080200371-A1 | THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES | IMPINJ, INC. | 2008-08-21 | — | — | US | disclosed |
| US-7381736-B2 | Thiazole and thiadiazole inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1841749-A1 | DERIVATIVES OF THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES | Metabasis Therapeutics, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1765332-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060194768-A1 | Thiazole and thiadiazole inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-08-31 | — | — | US | disclosed |
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006028970-A1 | DERIVATIVES OF THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006009876-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | PTPA, PTPN1, PTPRS | LAP3 1859/4885 |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, HRAS, APC | LAP3 3035/4885 |
| US-20140135309-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | NEK5, SIK2, SGK2 | LAP3 4717/4885 |
| US-20060194768-A1 | Thiazole and thiadiazole inhibitors of tyrosine phosphatases | PTPN1, PTPN5, PTPN18 | LAP3 1312/4885 |
| US-20080200371-A1 | THIAZOLE AND THIADIAZOLE INHIBITORS OF TYROSINE PHOSPHATASES | PTPN1, PTPN5, PTPN18 | LAP3 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.